Kevin Balthaser - 31 Dec 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Financial Officer
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
31 Dec 2024
Net transactions value
-$94,788
Form type
4
Filing time
03 Jan 2025, 18:25:10 UTC
Previous filing
04 Sep 2024
Next filing
04 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +73,750 +299% 98,447 31 Dec 2024 Direct F1
transaction ACRS Common Stock Tax liability $76,215 -30,732 -31% $2.48 67,715 31 Dec 2024 Direct F2
transaction ACRS Common Stock Options Exercise +7,500 +11% 75,215 01 Jan 2025 Direct F1
transaction ACRS Common Stock Tax liability $6,026 -2,430 -3.2% $2.48 72,785 01 Jan 2025 Direct F2
transaction ACRS Common Stock Options Exercise +13,200 +18% 85,985 02 Jan 2025 Direct F1
transaction ACRS Common Stock Tax liability $12,546 -5,059 -5.9% $2.48 80,926 02 Jan 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -73,750 -50% $0.000000 73,750 31 Dec 2024 Common Stock 73,750 Direct F1, F3
transaction ACRS Restricted Stock Units Options Exercise $0 -7,500 -33% $0.000000 15,000 01 Jan 2025 Common Stock 7,500 Direct F1, F4
transaction ACRS Restricted Stock Units Award $0 +40,000 $0.000000 40,000 02 Jan 2025 Common Stock 40,000 Direct F1, F5
transaction ACRS Restricted Stock Units Options Exercise $0 -13,200 -33% $0.000000 26,800 02 Jan 2025 Common Stock 13,200 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3 50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F4 On February 1, 2023, the Reporting Person was granted 30,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
F5 The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.